Stability of The ColonSentry® Colon Cancer Risk Stratification Test. Int J Dis Markers: IJDM-101. DOI: 10.29011 (2019 Jan)
A Blood-based Biomarker Panel for Stratifying Current Risk for Colorectal Cancer International Journal of Cancer: 126, 1177 (2009 Jul)
Blood RNA Biomarker Panel Detects Both Left- and Right-sided Colorectal NeoplasmsNext Generation Dx Summit (2010) Poster;Chao S, Ying J, Liew G, et al.
A case-controlled Validation Study of a Blood-based Seven-gene Biomarker Panel for Colorectal Cancer in Malaysia Journal of Experimental & Clinical Cancer Research: 29, 128 (2010), Yip KT, Das P, Suria D, et al.
Peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool Journal of Laboratory and Clinical Medicine. 2006;147:126-32.Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA
Prostate Health Index
Improving the Prediction of Pathologic Outcomes in Patients Undergoing Radical Prostatectomy:
The Value of Prostate Cancer Antigen 3 (PCA3), Prostate Health Index (Phi) and Sarcosine
Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. Journal of Urology, 2011
Evaluation of [ − 2] proPSA and Prostate HealthIndex (phi) for the detection of prostate cancer:
a systematic review and meta-analysis
The Prostate Health Index: a new test for the detection of prostate cancer, Stacy Loeb and William J. Catalona, PHI a New PCa Test Catalona-Loeb 2014
Melander O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6.
Melander O, Orho-Melander M, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J Clin Oncol. 2015 Aug 20;33(24):2632-8
Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78
Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 2012;308:1469–75.